Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab for MMR-D/MSI-H Colorectal Cancers
NCT06365970Phase 2Withdrawn
- Sponsor
- Ibrahim Halil Sahin
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib in colorectal cancer (CRC), sponsored by Ibrahim Halil Sahin. Planned start Jan 2025; status: withdrawn.
02
Drugs
niraparib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06365970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365970.